Ann: Notices received under s203D and s249D of Corporations Act, page-72

I just can't fathom that all the below data is now worth $0.

And was September's news release about Autoimmune Epilepsy a bridge to what was already known by Charmaine and Garner?

Where did Epilepsy come from - i thought it was pretty random at the time when all focus was on DMD.

The Proteomics blood analysis
- Statistically significant mean modulation at 24 weeks compared to baseline in Thrombospondin1 (TSP-1) and Latent TGF-beta-binding protein 4 (LTBP4) levels, two proteins that modify the rate of loss of ambulation in DMD
- Increase at 24 weeks in plasma VCAM-1 supportive of the ATL1102 mechanism of action of reducing CD49d on the surface of cells to which soluble VCAM-1 is bound, and in CXCL16 which can promote muscle regeneration
- Positive effects on LTBP4 and TSP-1 positions ATL1102 as an exciting prospect for the treatment of both non-ambulant and ambulant patients with DMD and the treatment of other muscle and fibrotic conditions

Significant modulation of two bone morphogenetic proteins supports potential of ATL1102
Statistically significant mean increases in BMP-5 (46.2%) and BMP-6 (34.4%) were observed at 24 weeks compared to baseline levels (FDR p-value <0.0005). When compared to an external healthy adult proteomics dataset used as a control, the baseline BMP-5 and BMP-6 levels of patients in the Phase II study were below average with the levels of each protein increasing to near the external healthy adult control mean by the end of the 24 week ATL1102 dosing period.

The positive DMD combo study...
RNA-seq transcriptomics results support the role of ATL1102, as monotherapy and in combination with a dystrophin exon skipping restoration agent, in reducing inflammation and augmenting muscle recovery

Limb Girdle R2 animal study - positive results...
In a mouse model of LGMDR2, treatment with ATL1102 partially normalised the function and physiology of the calf muscles to those of healthy animals.

AVICURSEN (ATL1102) shows positive signals in Autoimmune Epilepsy
Murine analogue of avicursen in a mouse model of autoimmune epilepsy showed a reduction in median seizure frequency of 66% for the drug when compared to a saline control. The reduction was statistically significant.